MedTrace Logo

Evaluation of Smoked THC and CBD in Men and Women

NCT05037487 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-03-20

No results posted yet for this study

Summary

The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of inhaled cannabis with varying amounts of delta-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.

Conditions

  • Drug Abuse
  • Intoxication by Drug
  • Impairment

Interventions

DRUG

Placebo Cannabis

Smoked placebo cannabis

DRUG

20 mg CBD Cannabis

Smoked cannabis with CBD

DRUG

20 mg CBD + 20 mg THC Cannabis

Smoked cannabis with CBD and THC

DRUG

20 mg THC Cannabis

Smoked cannabis with THC

Sponsors & Collaborators

Principal Investigators

  • Ziva Cooper, PhD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2025-01-07
Completion
2025-06-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05037487 on ClinicalTrials.gov